Strategy of transfusion in cardiac surgery: limits of hematocrit and how much is too low?

Author: Jakobsen, Carl-Johan

Source: Future Cardiology, Volume 3, Number 2, March 2007 , pp. 141-151(11)

Publisher: Future Medicine

Purchase options

The full text electronic article is available for purchase. You will be able to download the full text electronic article after payment.

$73.00 plus tax      Refund Policy

OR

 
More about this publication?
More like this?
Content Key:
Free Content - Free
New Content - New
Open Access Content - Open Access
Subscribed Content - Subscribed
Free Trial Content - Free Trial

Abstract:

The use of blood and blood products in cardiac surgery is higher than necessary and a reduction is imperative due to complications and costs. Hemodilution is unavoidable in cardiopulmonary bypass and is the most likely pitfall when evaluating transfusion needs. Even patients with coexisting cardiovascular diseases tolerate perioperative hemodilution better than most anticipate. Hemodynamic monitoring is important to evaluate the association between hemoglobin level and organ function. Use of both mechanical and medical blood conservation strategies is required to reduce blood transfusion, and most of the methods have a positive cost-effectiveness and cost-benefit. By using the right strategy and policy, transfusion of blood and blood products can be reduced to less than 5% of cardiac patients.

Keywords: aprotinin; autolog transfusion; cardiac surgery; erythropoietin; hematocrit; hemodilution; hemodynamics; transfusion

Document Type: Research article

DOI: 10.2217/14796678.3.2.141

Back to top

Content Key:
Free Content - Free
New Content - New
Open Access Content - Open Access
Subscribed Content - Subscribed
Free Trial Content - Free Trial
Share this item with others: These icons link to social bookmarking sites where readers can share and discover new web pages.
Page Help Click here for Page Help
Shopping cart
Tools
Sign in
Need to register?
Sign up here
Text size: A | A | A | A